Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Tesla Q1 2026 Deliveries Miss Estimates as AI Strategy Takes Center Stage 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
BHP's Incoming CEO Visits China Amid Pricing Dispute with CMRG 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
Britain Courts Anthropic Amid US Defense Department Dispute 
Alibaba Shares Slide as Jefferies Slashes Price Target Over AI Spending and Business Losses 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
Pony.ai, Uber, and Verne Launch Europe's First Commercial Robotaxi Service in Zagreb 
SpaceX IPO: Retail Investors to Play Historic Role in Record-Breaking Public Offering 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
WESTLAKE VILLAGE, Calif., Aug. 01, 2017 -- Sienna Biopharmaceuticals, Inc. (NASDAQ:SNNA) today announced the closing of the Company’s initial public offering of 4,983,333 shares of common stock at a public offering price of $15.00 per share, which includes the exercise in full by the underwriters of their option to purchase up to an additional 650,000 shares of common stock. Aggregate gross proceeds to the Company were approximately $74.7 million, before underwriting discounts, commissions and estimated offering expenses. All of the shares in the offering were offered by Sienna. Sienna’s common stock is listed on The NASDAQ Global Select Market under the ticker symbol “SNNA.”
J.P. Morgan and Cowen acted as joint book-running managers for the offering. BMO Capital Markets also acted as bookrunner for the offering.
A registration statement relating to the shares sold in this offering was declared effective by the Securities and Exchange Commission on July 26, 2017. The offering was made only by means of a prospectus. Copies of the prospectus may be obtained from J.P. Morgan, by mail at J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; from Cowen, by mail at Cowen and Company, LLC, c/o Broadridge Financial Services, 1155 Long Island Avenue, Edgewood, NY 11717, Attention: Prospectus Department, or by telephone at (631) 274-2806; or from BMO Capital Markets, by mail at BMO Capital Markets Corp., c/o 3 Times Square, 25th Floor, New York, NY 10036, Attention: Syndicate Department, or by telephone at (800) 414-3627.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Sienna Biopharmaceuticals
Sienna Biopharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on bringing innovations in biotechnology to the discovery, development and commercialization of first-in-class, targeted, topical products in medical dermatology and aesthetics. Sienna’s objective is to develop an innovative, diversified, multi-asset pipeline of topical therapies that enhance the health, appearance and quality of life of dermatology and aesthetics patients. Sienna is led by a management team with extensive experience in product development and commercialization at several leading dermatology, aesthetics and biotechnology companies.
Contact (Investors and Media): Ric Peterson Chief Financial Officer [email protected] 818-629-2232 Sean Andrews Senior Director, Investor Relations [email protected] 818-629-2244
